Molecular Network Pathway of ERBB In Diffuse-Type Gastric Cancer: Mesenchymal Stem Cells and Epithelial-Mesenchymal Transition

Abstract

Epithelial-mesenchymal transition (EMT) is related to malignancy and metastasis in cancer. The molecular networks including tyrosine kinases are altered in gastric cancer (GC). This study aims to reveal the role of ERBBs (erb-b2 receptor tyrosine kinases) in EMT, and generate the molecular network pathway of ERBBs in diffuse-type GC and mesenchymal stem cells (MSCs). The expression of ERBB genes was analyzed in MSCs and diffuse-type GC which has mesenchymal characteristics compared to intestinal-type GC. The signaling and molecular network of ERBB was analyzed using several databases, including cBioPortal for Cancer Genomics, Kyoto Encyclopedia of Genes and Genomes (KEGG), BioGRID and VaProS. ERBB2 and ERBB3 gene expression were up-regulated in diffuse-type GC compared to MSCs. The ERBB3 molecular network includes epidermal growth factor receptor (EGFR), cadherin 1 (CDH1), catenin beta 1 (CTNNB1) and EPH receptor A5 (EPHAS). These results demonstrate the importance of the ERBB network in cancer signaling, and revealed a ERBB3 network pathway model in diffuse-type GC and MSCs, and EMT.

Keywords: Epithelial-mesenchymal transition; Gastric cancer; Mesenchymal stem cell; ERBB; Stem cell

Introduction

An abundance of molecular signaling pathways are linked between stem cells and cancer. As cellular phenotype changes, expression levels of specific genes in these signaling pathways are altered. We have previously investigated CTNNB1 networks in epithelial-mesenchymal transition (EMT), and revealed that the CTNNB1 network includes epidermal growth factor receptor (EGFR) and erb-b2 receptor tyrosine kinase (ERBB2) [1]. The ERBB family includes EGFR (ERBB1 or HER1), ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4) [2]. Previous studies have demonstrated that ERBB family members are important for cancer, and so in this article, we analyzed the ERBB network [3-5]. ERBB2 and ERBB3 were found to be overexpressed in an appendiceal adenocarcinoma in which p53 was inactivated and the Ras/RAF/MEK, Akt/mTOR, Wnt, and NOTCH pathways were activated [6]. Somatic mutations in ERBB3 were identified in a significant number of early-onset sporadic diffuse-type gastric cancer (GC) [7]. Mutations in extracellular domains of ERBB2 are suggested to be oncogenic in lung cancer [8].

Since previous reports have demonstrated that the ERBB members are involved in cancer and stem cell networks, it is important to elucidate the role of ERBBs in EMT and cancer resistance. To further reveal the mechanism of EMT in cancer and stem cells, we investigated the expression of ERBB genes in mesenchymal stem cells (MSCs) and diffuse-type GC, and generated ERBB network pathway model.
Materials and Methods

Gene expression analysis of MSCs and GC

Gene expression in MSCs (6 early- and 6 late-stage cultures, n=12) and diffuse-type GC (n=5) was analyzed with GeneChip® Human Genome U133 Plus 2.0 microarray (Affymetrix, Santa Clara, California, USA), as previously described [1,9,10]. Briefly, total purified cellular RNA was biotinylated and hybridized to the microarray. The signal intensity for each gene was analyzed and compared between MSCs and diffuse-type GC. The microarray data for MSCs and diffuse-type GC are available to the public in the NCBI Gene Expression Omnibus (GEO) database and are accessible via GEO Series accession number GSE7888 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE7888) and GSE42252 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42252), respectively [1,9,10].

Cell culture

Human MSCs from bone marrow (Lonza, Walkersville, MD, USA) were cultured in MSC growth medium (MSCGM; Lonza #PT-3003; MSC basal medium supplemented with mesenchymal cell growth supplement, L-glutamine and penicillin/streptomycin) at 37°C in a CO₂ (5%) incubator. Cells were passaged according to the manufacturer’s protocol, however a slight modification was made to use trypsin-EDTA solution (Lonza #CC-3232). Lot numbers of the human MSC batches were as follows: #4F1127, #4F0312, #5F0138, #4F1560, #4F0591 and #4F0760. Informed consent was obtained for Poietics human MSC systems (Lonza) [10]. Passage numbers of MSC cultures were #4 and #22 for #4F1127, #4 and #28 for #4F0312, #4 and #24 for #5F0138, #5 and #28 for #4F1560, #4 and #28 for #4F0591, and #4 and #28 for #4F0760.

Diffuse-Type GC tissues

Diffuse-type GC tissues were originally provided by the National Cancer Center Hospital after obtaining written informed consent from each patient and approval from the National Cancer Center Institutional Review Board. All cancer specimens were reviewed from each patient and approval from the National Cancer Center Hospital after obtaining written informed consent. Studies of stomach adenocarcinoma (TCGA, Nature 2014) were further analyzed for pathway network analysis [13].

Analysis with Cbioportal for Cancer Genomics

cBioPortal for Cancer Genomics (http://www.cbioportal.org) [11,12] was used to analyze cancer genomics data related to ERBB3. The term “ERBB3” was searched in the cBioPortal for Cancer Genomics, and the cross-cancer alteration summary for ERBB3 was obtained. Studies of stomach adenocarcinoma (TCGA, Nature 2014) were further analyzed for pathway network analysis [13].

Gene Ontology Analysis of ERBB3

Gene Ontology of ERBB3 was analyzed using several databases, including the DAVID (https://david.ncifcrf.gov/home.jsp), EMBL-EBI (http://www.ebi.ac.uk/QuickGO/), AmiGO 2 (http://amigo.geneontology.org/amigo/landing) and the Gene Ontology Consortium (http://geneontology.org/).

Pathway Network Analysis of ERBB3 and Related Genes

Pathway network analysis was performed using the databases VaProS (http://pford.info/vapros/), KEGG (http://www.genome.jp/kegg/), cBioPortal for Cancer Genomics (http://www.cbioportal.org), and Cytoscape (http://www.cytoscape.org/). Molecular interactions were analyzed using the BioGRID (http://www.thebiogrid.org) database [14]. Molecule localization was analyzed using The Human Protein Atlas (http://www.proteinatlas.org/) [15] and UniProt (http://www.uniprot.org/) [16].

Statistical Analysis

The gene expression data was shown in signal intensity or ratio to the average of MSC expression. The ratio to the mean of signal intensity in MSC samples normalized with GAPDH signal intensity was calculated and averaged. The data were shown as the mean ± SE. Student’s t-test was performed in Microsoft Excel (Microsoft, Redmond, WA, USA). p<0.001 (n=12 in MSCs, n=5 in diffuse-type GC) was considered as statistically significant.

Results

Gene expression of EGFR, ERBB2 and ERBB3 in MSCs and diffuse-type GC

Expression levels of the EGFR, ERBB2 and ERBB3 genes were analyzed in diffuse-type GC and MSCs (Figure 1A). ERBB2 gene expression was up-regulated approximately 3-fold in diffuse-type GC compared to MSCs (Figure 1B). ERBB3 gene expression was up-regulated by approximately 150-fold in diffuse-type GC compared to MSCs (Figure 1C). Signal intensity of the ERBB3 gene expression in each sample is shown in Figure 1D. ERBB4 signal intensity was low.

ERBB3 Interaction Analysis

ERBB3 interactions were analyzed using BioGRID database (Figure 2). ERBB3 interactors included growth factor receptor bound protein 2 (GRB2), phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2), C-terminal Src kinase (CSK), SHC adaptor protein 1 (SHC1) and epidermal growth factor (EGF) [2,17].

Network Pathway Analysis of ERBB3

cBioPortal for Cancer Genomics network pathway analysis revealed the ERBB3-associated network and ERBB3 cross-cancer alterations (Figure 3A and B). The ERBB3 molecular network was analyzed in stomach adenocarcinoma (TCGA, Nature 2014, tumor samples with sequencing and CNA data 287 samples / 1 gene) [13]. The network contained 51 nodes and included the
1 query gene ERBB3 as well as the 50 most frequently altered neighboring genes (out of a total of 420) in cBioPortal (Table 1). The network shown in Figure 4 includes the 1 originally queried core gene and the 50 neighboring genes. Analysis of molecular interactions in VaProS demonstrated that ERBB3 interacts with neuregulin 1 (NRG1) and SH2B adaptor protein 3 (SH2B3).

Model Network of ERBB3

The model ERBB3 interaction network is shown in Figure 4. Nodes are colored based on gene expression alteration in diffuse-type GC compared to MSCs. Pink nodes indicate up-regulated (UR) genes and blue nodes indicate down-regulated (DR) genes with FC>3, p value <0.01. UR genes with 2<FC<3, p value <0.01 are highlighted with orange.
Table 1 Molecules in ERBB3 network.

| Gene Symbol | Gene Title                                      | Entrez Gene | Probe Set ID       |
|-------------|-------------------------------------------------|-------------|--------------------|
| BLK         | BLK proto-oncogene, Src family tyrosine kinase | 640         | 206255_at          |
| CDH1        | cadherin 1                                      | 999         | 201131_s_at        |
| CDH10       | cadherin 10                                     | 1008        | 220115_s_at        |
| CDH12       | cadherin 12                                     | 1010        | 207149_at          |
| CDH18       | cadherin 18                                     | 1016        | 206280_at          |
| CDH20       | cadherin 20                                     | 28316       | 210913_at          |
| CDH23       | cadherin related 23                             | 100653137/64072 | 224527_at |
| CDH4        | cadherin 4                                      | 1002        | 239485_at          |
| CDH6        | cadherin 6                                      | 1004        | 205532_s_at        |
| CDH8        | cadherin 8                                      | 1006        | 217574_at          |
| CDH9        | cadherin 9                                      | 1007        | 207729_at          |
| CELSR1      | cadherin EGF LAG seven-pass G-type receptor 1   | 9620        | 41660_at           |
| CELSR2      | cadherin EGF LAG seven-pass G-type receptor 2   | 1952        | 36499_at           |
| CELSR3      | cadherin EGF LAG seven-pass G-type receptor 3   | 1951        | 40020_at           |
| CTNNB1      | catenin beta 1                                 | 1499        | 223679_at          |
| CUX1        | cut like homeobox 1                             | 1523        | 225935_at          |
| DCHS1       | dachsous cadherin-related 1                     | 8642        | 222101_s_at        |
| DVL3        | dishevelled segment polarity protein 3          | 1857        | 201908_at          |
| EGFR        | epidermal growth factor receptor                | 1956        | 201983_s_at        |
| EPHA2       | EPH receptor A2                                 | 1969        | 203499_at          |
| EPHA5       | EPH receptor A5                                 | 2044        | 237939_at          |
| EPHB3       | EPH receptor B3                                 | 2049        | 204600_at          |
| ERBB3       | erb-b2 receptor tyrosine kinase 3               | 2065        | 202454_s_at        |
| ERBB4       | erb-b2 receptor tyrosine kinase 4               | 2066        | 214053_at          |
| FAT1        | FAT atypical cadherin 1                         | 2195        | 201579_at          |
| FAT2        | FAT atypical cadherin 2                         | 2196        | 208153_s_at        |
| FAT3        | FAT atypical cadherin 3                         | 120114      | 236029_at          |
| FGF10       | fibroblast growth factor 10                     | 2255        | 231762_at          |
| FGFGR2      | fibroblast growth factor receptor 2             | 2263        | 208228_s_at        |
| GRB7        | growth factor receptor bound protein 7          | 2886        | 210761_s_at        |
| IGF1R       | insulin like growth factor 1 receptor           | 3480        | 225330_at          |
| INPPL1      | inositol polyphosphate phosphatase like 1       | 3636        | 201598_s_at        |
| JAK2        | Janus kinase 2                                  | 3717        | 205841_at          |
| NF1         | neurofibromin 1                                 | 4763        | 212676_at          |
| NFATC2      | nuclear factor of activated T-cells 2           | 4773        | 228442_at          |
| PCDH10      | protocadherin 10                                | 57575       | 228635_at          |
| PCDH15      | protocadherin 15                                | 65217       | 1553344_at         |
| PCDH20      | protocadherin 20                                | 64881       | 232054_at          |
| PCDHA11     | protocadherin alpha 11                          | 56134 / 56135 / 56136 / 56137 / 56138 / 56139 / 56140 / 56141 / 56142 / 56143 / 56144 / 56145 / 56146 / 56147 / 9752 | 210674_s_at |
| PIK3C2B     | phoshatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 | 5287 | 204484_at |
| PIK3CA      | phoshatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 5290 | 204369_at |
| PIK3CG      | phoshatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | 5294 | 206369_s_at |
| PLCG1       | phospholipase C gamma 1                         | 5335        | 202789_at          |
| PRKCI       | protein kinase C iota                           | 5584        | 209678_s_at        |
| PTEN        | phosphatase and tensin homolog                  | 5728        | 233254_x_at        |
| PTK2        | protein tyrosine kinase 2                       | 5747        | 15595929_at        |
| SOS2        | SOS Ras/Rho guanine nucleotide exchange factor 2 | 6655 | 212870_at |
| SPTA1       | spectrin alpha, erythrocytic 1                  | 6708        | 206937_at          |
| SPTAN1      | spectrin alpha, non-erythrocytic 1              | 6709        | 208611_s_at        |
| SPTBN4      | spectrin beta, non-erythrocytic 4               | 57731       | 224551_s_at        |
| TNK2        | tyrosine kinase non-receptor                    | 10188       | 203839_s_at        |

Primary localization information was based on the Cell Atlas in the Human Protein Atlas where available. Secondary localization information was based on subcellular location information from the UniProt database. Gene ontology (GO) of molecules in the ERBB3 model network was related to Wnt receptor signaling.
pathway, cell adhesion, cell proliferation, cell differentiation and apoptosis.

KEGG pathway and Gene Ontology of ERBB3

According to KEGG pathway analysis, ERBB3 is involved with EGFR tyrosine kinase inhibitor resistance, the ErbB signaling pathway, the calcium signaling pathway, endocytosis, proteoglycans in cancer, and microRNAs in cancer. The GO of ERBB3 analyzed in AmiGO 2 includes the ERBB3 signaling pathway, the ERBB4-ERBB3 complex, the ERBB2-ERBB3 signaling pathway, and regulation of the ERBB3 signaling pathway (http://amigo.geneontology.org/amiigo/search/ontology?q=ERBB3). GO biological process of ERBB3 included transmembrane receptor protein tyrosine kinase signaling pathway and regulation of cell proliferation.

DAVID analysis of ERBB3 network molecules

Molecules of ERBB3 network were analyzed in Functional Annotation Tool of DAVID Bioinformatics Resources 6.8, NIAID/NIH (https://david.ncifcrf.gov/home.jsp). The Gene Ontology and Online Mendelian Inheritance in Man (OMIM) disease for the molecules of ERBB3 network were analyzed. Molecules in ERBB3 network are involved in cell adhesion or mitogen-activated protein kinase (MAPK) cascade.

Enrichment Analysis of ERBB3

The ERBB3 enrichment analysis using cBioPortal for Cancer Genomics revealed that the mRNA expression levels of DLG associated protein 3 (DLGAP3) and RNA polymerase II subunit J2 (POLR2J2) were altered in ERBB3-altered cases and ERBB3-unaltered cases in stomach adenocarcinoma (TCGA, Nature 2014) [13].

Discussion

In this study, we investigated the ERBB signaling role in EMT and cancer. Gene expression of ERBB3, as well as ERBB2, was up-regulated in diffuse-type GC compared to MSCs. ERBB3 network pathway model generated in this study included the EMT-related molecules such as CTNNB1 and CDH1. ERBB3 plays an important role in the PI3K/AKT pathway and is thus a target for the treatment of solid tumors [18]. Cell survival can be inhibited by a mouse monoclonal antibody against ERBB3 [18]. Expression of ERBB3 is correlated with intestinal stem cell markers such as LGR5, EPHB2, CD44 in colorectal cancer, although ERBB3 expression is observed in the differentiated cell population at the top of the crypts [19]. Furthermore, ERBB3 is targeted by mir-205-5p, a tumor suppressor in breast cancer [20]. Knockdown of ERBB3 suppressed migration and invasion of bladder cancer cells [21], miR-148a-3p targets both ERBB3 and AKT2 and may repress ERBB3- and AKT-mediated proliferation and EMT [21]. ERBB3 is characterized as a marker for circulating tumor cells exhibiting EMT phenotype and therapeutic resistance [22]. The activation of EGFR/EGFR-ErbB2 and NRG1/ErbB2-ErbB3 autocrine signaling loops drives triple negative breast cancer exhibiting the chemoresistance [23]. It seems that ErbB3 receptor is important for perineural migration to the bone marrow [24]. The previous immunohistopathology investigation showed that the ERBB2 and ERBB3 proteins were overexpressed in GC [25]. The previous finding indicating the correlation with ERBB3 overexpression and overall survival in GC is consistent with the present discussion in which ERBB3 up-regulation may be related to malignancy or the EMT network in GC [25]. A report suggests that ERBB2 and ERBB3 are down-regulated by DNA-damaging agent such as cisplatin via ERK and p38 signaling pathway [26]. It is also demonstrated that ERBB3 is involved in resistance to EGFR or ERBB2 targeted therapy for cancer [27]. Furthermore, the study of nanoparticles targeting ERBB2 and microRNA21 suggests the importance of ERBB signaling in cancer [28]. These insights indicate the significance of regulation of ERBB2 and ERBB3 signaling in cancer.

The down-regulation of ERBB3 following EMT leads to a reduction in serum-independent proliferation and an enhancement of PI3K-dependent proliferation [29]. Molecules related to intercellular adhesion and metastatic processes (such as PTEN) and endocytosis (such as ERBB3) are involved in liver metastasis [30]. In ERBB2-positive cancers, expression of EGFR, ERBB3 and CDKN1B are demonstrated to predict and distinguish the PI3K and MAPK signaling axes [31]. The ERBBs are inhibited by N-myc downstream regulated gene 1 (NDRG1) [32]. Since ERBBs are involved in oncogenic pathways, such as the PI3K, Akt and STAT3 pathways, further investigation of targeted molecules in the ERBB network is needed. Considering that the cancer cells migrating and metastasizing exhibit EMT-like phenotype, the investigation of ERBB3 signaling in bone-marrow derived MSCs showing mesenchymal phenotype and diffuse-type GC that exhibits more EMT-like phenotype compared to intestinal-type GC may lead to the novel discoveries for the overcome of the therapeutic resistance. Although the current finding showing ERBB3 gene up-regulation in diffuse-type GC compared to MSCs needs to be further examined in terms of the discussion whether the ERBB3 plays crucial role in EMT or not, it is suggested that the ERBB3 signaling is activated in gastric cancer. To further investigate the role of ERBB3 signaling in EMT and CSCs, the analysis in diffuse-type GC and intestinal-type GC would be needed in future.
In conclusion, ERBB3 gene expression was up-regulated in diffuse-type GC compared to MSCs, and ERBB3 network pathway model in EMT was generated. The model of the ERBB3-related molecular network included the EMT-associated molecules such as CTNNB1 and CDH1.

Acknowledgement

We gratefully acknowledge Dr Ryoji Kushima for the pathological and clinical evaluations. We would also like to thank Ms. Rie Komatsuzaki and Ms. Fumiko Chiwaki for their technical assistance. This study was supported in part by the National Institute of Biomedical Innovation, the Ministry of Health, Labour and Welfare of Japan, National Cancer Center Research and Development Fund, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Princess Takamatsu Cancer Research Fund. The authors would like to thank Dr. Akihiko Hirose and Dr. Takashi Yamada for supporting the preparation of the manuscript. The authors would like to thank Prof. Kei Yura for introducing us to the VaProS database, which was used in part in this research. VaProS is a data-cloud developed by the Information Core of the Platform Project for Supporting Drug Discovery and Life Science Research (Platform for Drug Discovery, Informatics, and Structural Life Science) from the Japan Agency for Medical Research and Development (AMED).

References

1. Tanabe S, Kawabata T, Aoyagi K, Yokozaki H, Sasaki H (2016) Gene expression and pathway analysis of CTNNB1 in cancer and stem cells. World J Stem Cells 8: 384-393.
2. Schulze WX, Deng L, Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1: 2005.0008.
3. Yuan HH, Yang YN, Zhou JH, Li YJ, Wang LY, et al. (2017) siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells. Oncotarget 8: 52584-52593.
4. Beltrami CM, Dos Reis MB, Barros-Filho MC, Marchi FA, Kuasne H, et al. (2017) Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas. Clin Epigenetics 9: 45.
5. Bautz DJ, Sherpa AT, Threadgill DW (2016) Prophylactic vaccination targeting ERBB3 decreases polyp burden in a mouse model of human colorectal cancer. Oncoimmunol 6: e1255395.
6. Sheffielfs BS, Tressier-Cloutier B, Li-Chang H, Shen Y, Pleasance E, et al. (2016) Personalized oncogenecities in the management of gastrointestinal carcinomas-early experiences from a pilot study. Curr Oncol 23: e571-e575.
7. Cho SY, Park JW, Liu Y, Park YS, Kim JH, et al. (2017) Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOM2 Mutations Compared with Late-Onset Cancers. Gastroenterology 153: 536-549.
8. Greulich H, Kaplan L, Mertins P, Chen TH, Tanaka KE, et al. (2012) Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 109: 14476-14481.
9. Tanabe S, Aoyagi K, Yokozaki H, Sasaki H (2014) Gene expression signatures for identifying diffuse-type gastric cancer associated with epithelial-mesenchymal transition. Int J Oncol 44: 1955-1970.
10. Tanabe S, Sato Y, Suzuki T, Suzuki K, Nagao T, et al. (2008) Gene expression profiling of human mesenchymal stem cells for identification of novel markers in early- and late-stage cell culture. J Biochem 144: 399-408.
11. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: p11.
12. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. (2012) The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404.
13. Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202-209.
14. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, et al. (2006) BioGRID: A general repository for interaction datasets. Nucleic Acids Res 34: D535-D539.
15. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, et al. (2015) Proteomics: Tissue-based map of the human proteome. Science 347: 1260419.
16. The UniProt Consortium (2017) UniProt: the universal protein knowledgebase. Nucleic Acids Res 45: D158-D169.
17. Stortelers C, Souriau C, van Lienpt E, van de Poll ML, van Zoelen EJ (2002) Role of the N-terminus of epidermal growth factor in ErbB-2/Erbb-3 binding studied by phage display. Biochemistry 41: 8732-8741.
18. Xiao Z, Carrasco RA, Schifferli K, Kinneer K, Tammali R, et al. (2016) A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response. Mol Cancer Ther 15: 689-701.
19. Jardè T, Kass L, Staples M, Lescesen H, Carne P, et al. (2015) ERBB3 Positively Correlates with Intestinal Stem Cell Markers but Marks a Distinct Non Proliferative Cell Population in Colorectal Cancer. PLoS One 10: e0138336.
20. De Cola A, Volpe S, Budani MC, Ferracin M, Lattanzio R, et al. (2015) miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death Dis 6: e1823.
21. Wang X, Liang Z, Xu X, Li J, Zhu Y, et al. (2016) miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. Cell Death Dis 7: e2503.
22. Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, et al. (2016) Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget 7: 41677-41690.
23. Blanchard Z, Paul BT, Craft B, ElShamy WM (2015) BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast Cancer Res 17: 5.
24. Isen J, García-García A, Martin AM, Arranz L, Martín-Pérez D, et al. (2014) The neural crest is a source of mesenchymal stem cells with specialized hematopoietic stem cell niche function. Elife 3: e03696.
25. Cao G, Chen K, Chen B, Xiong M (2017) Positive prognostic value of
HER2-HER3 co-expression and p-mTOR in gastric cancer patients. BMC Cancer 17: 841.

26 Park CM, Kawasaki Y, Refaat A, Sakurai H (2018) Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways. Oncol Lett 15: 1758-1762.

27 Mishra R, Hanker AB, Garrett JT (2017) Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 8: 114371-114392.

28 Hu N, Yin JF, Ji Z, Hong Y, Wu P, et al. (2017) Strengthening gastric cancer therapy by trastuzumab-conjugated nanoparticles with simultaneous encapsulation of anti-miR-21 and 5-fluorouridine. Cell Physiol Biochem 44: 2158-2173.

29 Salt MB, Bandyopadhyay S, McCormick F (2014) Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov 4: 186-199.

30 Sayagués JM, Corchete LA, Gutiérrez ML, Sarasquete ME, Del Mar Abad M, et al. (2016) Genomic characterization of liver metastases from colorectal cancer patients. Oncotarget 7: 72908-72922.

31 Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, et al. (2016) HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. PLoS Comput Biol 12: e1004827.

32 Menezes SV, Sahni S, Kovacevic Z, Richardson DR (2017) Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling. J Biol Chem 292: 12772-12782.